ellacor System for Skin Tightening

Ellacor

ACPS is excited to be the very first plastic surgery office to offer ellacor®. ellacor is a revolutionary device from medical technology company Cytrellis. This minimally invasive treatment uses Micro-Coring™ technology to diminish wrinkles and age-related skin laxity in the mid to lower face. Clinical studies of ellacor report a 91% improvement of moderate to severe wrinkle/s and a very high rate of patient satisfaction.

How does ellacor work?

ellacor is one of the first devices to use a fractional tissue extraction process called micro-coring to rejuvenate skin. Advanced signs of facial aging, such as deep wrinkles and sagging skin, can be difficult to treat effectively without surgery. ellacor can deliver smoother, tighter, younger looking skin without surgery and without any scarring. The ellacor device allows for micro-excisional removal of excess skin with very fine hollow needles. The needles are small and precise enough to reach the full thickness of the skin without leaving any scarring.

Benefits

  • No incisions or scarring
  • Removes excess, sagging skin
  • Diminishes the appearance of wrinkles
  • Can reduce the appearance of “marionette lines” and jowls
  • Results are visible while also natural-looking
  • In- office treatment with no general anesthesia needed

How is ellacor different from other skin revitalization devices?

ellacor removes micro-portions of excess skin to achieve an improvement in the appearance of wrinkles, whereas many other skin revitalization devices use heat generated by laser, radio frequency and ultrasound energy to induce intentional thermal injury to the skin.

What to Expect

A local anesthetic will be administered to the area to be treated to help you stay comfortable during your treatment. Once your skin is numb, your provider will strategically place ellacor device to your skin to create micro-cores in a precise grid pattern. Excess skin will be removed through the hollow needles, but the micro-cores are so tiny that they will begin to heal almost immediately.

An ellacor® procedure typically takes about 30 minutes or less depending on the area. First, your skin will be numbed with a local anesthetic, then your provider will strategically place the ellacor® device on your skin to create micro-cores in a precise grid pattern. Excess skin is removed through the hollow needles, but the micro-cores are so tiny that they will begin to heal almost immediately. After your treatment the recovery takes up to one week of downtime or until you are comfortable having your face seen in public. 

Call our office for more information at 713-799-9999 

INDICATION FOR USE

The ellacor® System with Micro-Coring™ technology is indicated for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV.

IMPORTANT SAFETY INFORMATION

RISKS & BENEFITS

Your medical professional will discuss the following side effects with you prior to treatment. Proper pre- and post-treatment care reduces the risk of these side effects; however, some conditions may or may not resolve over time. Side effects associated with this procedure may include: redness, swelling, bruising, burning, dryness, roughness, tightness/pulling of skin, crusting, pain/discomfort, tenderness, tingling, bleeding, numbness, skin peeling, or circular marks on skin.

Other side effects not commonly observed with this procedure may include: itching, hyper/hypo pigmentation, hematoma, infection, scarring, skin irregularities, skin necrosis, uneven appearance of the treated regions (left and right sides of face), or anesthesia toxicity (anesthesia-related complications may include allergic reaction and possibly death).

CONTRAINDICATIONS

The ellacor® procedure should not be used for the treatment of areas of skin with dermatosis (e.g. skin tumors, keloids or in case of predisposition to keloids, solar keratosis, warts, or birthmarks), area within the bony orbital rim; mucous membranes; areas where silicone or synthetic material is implanted.

The ellacor® procedure should not be used on patients that are pregnant or nursing mothers, suffering from open wounds, sores, or irritated skin in the treatment area, have an allergy to stainless steel or allergy to topical, oral, or injected medications or preparations that may be used during the procedure, such as petrolatum, lidocaine, bupivacaine, chlorhexidine, or povidone-iodine. Patients that have a history or presence of any clinically significant bleeding disorder, have dermatological or autoimmune conditions that may affect the treatment outcome; these may include, but are not limited to: actinic keratosis, raised nevi, rosacea, melasma, active acne, cutaneous papules/nodules, active inflammatory lesions, dermatitis, psoriasis, cellulitis, urticarial folliculitis, acute inflammatory phase of scleroderma, rheumatoid arthritis, eczema, psoriasis, allergic dermatitis, collagen disorders, or lupus should not be treated with the ellacor® procedure. Additionally, patients that have systemic infections or acute local skin infections such as Hepatitis disorders type A, B, C, D, E or F or HIV infection, take a high dose of anti-coagulants or blood-thinning substances (e.g. aspirin, nonsteroidal anti-inflammatory drugs, NSAIDs, warfarin, heparin, acetylsalicylic acid during the previous fourteen (14) days), are on courses of chemotherapy, high-dose corticosteroid use, or radiation in the treatment area, have undergone plastic surgery of the face within the last twelve (12) months or have any facial surgical scars less than twelve (12) months old, have undergone injections of dermal fillers, fat, or botulinum toxin, as well as any minimally invasive/invasive skin treatment in the treatment area during the previous six (6) months, or have scars less than six (6) months old in the treatment area should not be treated with the ellacor® procedure.

TREATMENT PRECAUTIONS

Appropriateness for treatment is based on the clinical assessment of the patient by the treating physician. Use caution when treating patients with the following conditions or taking the following medications:

  • History of hyperpigmentation
  • Recent exposure to sun or tanning beds with red, peeling, or swollen skin
  • Active, chronic, or recurrent infection including bacterial or fungal infections
  • History of active herpes simplex infection in the treatment area
  • Use of topical or oral preparations/medications that may change the skin integrity or prolong healing
  • Over the Counter (OTC) and herbal supplements that may increase the risk of bleeding or prolong healing, such as gingko biloba, garlic, ginseng, dong quai, fever few, and fish oil
  • Other medications or medical conditions that may interfere with the treatment or that the treatment provider believes may compromise the safety of the patient or the efficacy of the treatments. Refer the patient to their Primary Care Physician (PCP) or other managing health care provider or clearance prior to treatment
  • Recent trauma or surgery to the treatment area
  1. Pivotal Study to Evaluate the Effectiveness of a Micro-Coring Device Treating Moderate to Severe Facial Wrinkles. ClinicalTrials.gov NCT 03573271; submitted for publication. 51 subjects completed the pivotal study; subjects were treated 2-3 times with 7%-8% skin removal and up to 5mm needle coring depth. Each patient heals differently; mild to moderate side effects may still be present up to 30 days post-treatment per physician assessment. All clinical data, including patient healing, treatment pain on the 0-10 Wong-Baker Scale, Global Aesthetic Improvement Scale scores, and Subject Satisfaction is on file with Cytrellis.
  2. Champlain, A. et al. 2019. What is the Largest Size Full-Thickness Skin Injury That Can Heal Without a Scar? Lasers in Surgery and Medicine, 50(S30), S30-31. https://doi.org/10.1002/lsm.23059
  3. Cytrellis data on file.
  4. Cytrellis studies using OCT (Optical Coherence Tomography) have demonstrated absence of holes, approximately 10 minutes post procedure (2017)